- Resistance to chemotherapy may be caused by vascular endothelial growth factor receptor 2 (VEGFR-2) signaling.
- Resistance to chemotherapy is common in leukemia.
- The discovery of this underlying mechanism may help enhance the effectiveness of chemotherapy.
The mechanism through which certain types of leukemia resist chemotherapy has been identified by recent research at the Instituto de Medicina Molecular (iMM) João Lobo Antunes.
The culprit in chemotherapy resistance
In patients with acute myeloid leukemia, cancer cells resist the effects of chemotherapy, many times resulting in disease recurrence and ultimately death.
The team, led by Sérgio Dias, had previously shown that leukemic cells activate certain molecular signals, namely a cell signaling pathway controlled by the Endothelial Vascular Growth Factor (VEGF), which allow cancer cells to survive despite chemotherapy.
Overcoming resistance to chemotherapy drugs
Using drugs that specifically blocked VEGF's activation, it was possible to revert these mitochondrial modifications and render these cells vulnerable to chemotherapy.
"Our study contributes to an improved understanding of how cellular metabolism plays an important role in the acquisition of resistance to certain therapeutic agents," said Sérgio Dias.
These newly discovered molecular targets will allow the development of therapeutic strategies that may be explored as possible routes to eliminate leukemic cells' resistance to chemotherapy.
- Sandrina Nóbrega-Pereira, Francisco Caiado et al. VEGFR-2-Mediated Reprogramming of Mitochondrial Metabolism Regulates the Sensitivity of Acute Myeloid Leukemia to Chemotherapy, Cancer Research DOI: 10.1158/0008-5472.CAN-17-1166